View clinical trials related to Acute Myeloid Leukemia NOS.
Filter by:Primary Objective: Measure the proportion of patients who develop binding and neutralizing antibodies in the blood after treatment with sargramostim following induction/reinduction chemotherapy. Secondary Objectives: - Assess the time after treatment at which the antibodies develop and the level of antibodies is measured after the first dose. - Measure the levels of immunoglobulin protein. - Assess the impact of any immune response on safety and the duration of low white blood cell count.